We are an innovation focused biotech company dedicated to delivering next-generation multispecific antibody therapeutics so more people with cancer and other serious diseases can live longer and improved lives.
Our clinically validated multispecific antibody platform has delivered a deep proprietary and partnered pipeline of promising clinical and preclinical drug product candidates.
The “plug-and-play” format of our Fcab® and mAb2® technology platforms enables rapid discovery of differentiated drug product candidates with a natural human antibody format that allows for a straightforward manufacturing process, favourable safety profile and strong biological potency.
In 2023, F-star was acquired by invoX Pharma, a fully integrated biopharmaceutical company, wholly owned by Sino Biopharm.
Leadership
Our executive leadership team members have extensive experience in immuno-oncology and have worked with global pharmaceutical companies as well as biotechs, with a well-established track record of building biotech companies and developing biologics.
Neil Brewis
Head of F-star and CSO
Neil Brewis
Head of F-star and CSO
Over 25 years of experience in antibody engineering and drug R&D and has successfully advanced novel platforms from inception to clinical proof of concept, with a therapeutic focus in oncology. Formerly at GSK and Domantis Ltd.
Andrew Aitken
Head of IT, Data & Business Assurance
Andrew Aitken
Head of IT, Data & Business Assurance
Michelle Morrow
SVP, Head of Research
Michelle Morrow
SVP, Head of Research
Rosie Almond
Head of HR
Rosie Almond
Head of HR
Pauline Stevens
Head of Business Operations
Pauline Stevens
Head of Business Operations
Lara Boyd
VP, Head of BD & Corporate Strategy
Lara Boyd
VP, Head of BD & Corporate Strategy
Carys Jones
Head of Finance
Carys Jones
Head of Finance
Pharmaceutical Partnerships
F-star’s platform has been validated through partnerships for over a decade. We have collaboration and licensing agreements with many leading biopharma companies to research, develop, and commercialize therapies leveraging our modular antibody technology and mAb2 programs. Our partners are targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS, among others.
2021: Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration
2020: Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration
2019: F-star expedites its transition to a wholly-owned portfolio strategy
2011: Joint discovery and development of new antibody-derived therapeutic products